Could Endo International plc – Ordinary Shares See a Reversal After Today’s Strong Options Activity?

 Could Endo International plc   Ordinary Shares See a Reversal After Today's Strong Options Activity?

In today’s session Endo International plc – Ordinary Shares (ENDP) registered an unusually high (1,114) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the December, 2016 call, expecting serious ENDP increase. With 1,114 contracts traded and 664 open interest for the Dec, 16 contract, it seems this is a quite bullish bet. The option with symbol: ENDP161216C00017500 closed last at: $1 or 100% up. About 1.53M shares traded hands. Endo International plc – Ordinary Shares (NASDAQ:ENDP) has declined 32.85% since April 11, 2016 and is downtrending. It has underperformed by 38.99% the S&P500.

Endo International plc – Ordinary Shares (NASDAQ:ENDP) Ratings Coverage

Out of 17 analysts covering Endo International plc (NASDAQ:ENDP), 11 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 65% are positive. $100 is the highest target while $20 is the lowest. The $54.31 average target is 218.16% above today’s ($17.07) stock price. Endo International plc has been the topic of 38 analyst reports since August 11, 2015 according to StockzIntelligence Inc. As per Thursday, January 21, the company rating was initiated by Barclays Capital. Piper Jaffray downgraded Endo International plc – Ordinary Shares (NASDAQ:ENDP) on Friday, May 6 to “Neutral” rating. The rating was maintained by Citigroup with “Buy” on Friday, April 29. As per Friday, October 9, the company rating was initiated by Mizuho. The firm has “Market Perform” rating by Northland Capital given on Wednesday, December 9. The stock has “Buy” rating given by Standpoint Research on Friday, November 13. The rating was maintained by JP Morgan with “Overweight” on Monday, March 21. The stock has “Buy” rating given by Deutsche Bank on Tuesday, September 29. The company was maintained on Friday, May 6 by Barclays Capital. The firm has “Market Perform” rating given on Friday, May 6 by Leerink Swann.

According to Zacks Investment Research, “Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology. The company also provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets. Endo International plc, formerly known as Endo Pharmaceuticals Holdings Inc., is headquartered in Dublin, Ireland.”

Insitutional Activity: The institutional sentiment increased to 0.95 in Q2 2016. Its up 0.03, from 0.92 in 2016Q1. The ratio is positive, as 76 funds sold all Endo International plc – Ordinary Shares shares owned while 90 reduced positions. 42 funds bought stakes while 115 increased positions. They now own 192.40 million shares or 1.49% more from 189.57 million shares in 2016Q1.
Jensen Mgmt last reported 0.01% of its portfolio in the stock. Blackstone Grp Lp has invested 0.05% of its portfolio in Endo International plc – Ordinary Shares (NASDAQ:ENDP). New York State Teachers Retirement accumulated 0.01% or 314,969 shares. The Wisconsin-based State Of Wisconsin Board has invested 0.01% in Endo International plc – Ordinary Shares (NASDAQ:ENDP). Oppenheimer And Com Inc owns 14,375 shares or 0.01% of their US portfolio. Envestnet Asset Mngmt holds 1,235 shares or 0% of its portfolio. The Connecticut-based Euclid Advsrs Ltd Com has invested 0.01% in Endo International plc – Ordinary Shares (NASDAQ:ENDP). British Columbia Inv Management reported 91,100 shares or 0.01% of all its holdings. Airain Limited, a Guernsey-based fund reported 128,005 shares. Sei last reported 34,152 shares in the company. Gargoyle Invest Advisor Limited Liability Corp holds 20,462 shares or 0.12% of its portfolio. The Pennsylvania-based Schneider Cap Mngmt has invested 1.3% in Endo International plc – Ordinary Shares (NASDAQ:ENDP). Monroe Hall Asset Llc last reported 2.42% of its portfolio in the stock. Td Asset Mgmt last reported 0% of its portfolio in the stock. Fincl Gru has 807,880 shares for 0.96% of their US portfolio.

ENDP Company Profile

Endo International plc, incorporated on October 31, 2013, is a global specialty pharmaceutical firm focused on developing, manufacturing, marketing and distributing branded and generic pharmaceutical products, as well as over-the-counter medications through its operating companies- Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs and SOMAR. The Company’s divisions include U.S. Branded Pharmaceuticals, which offer portfolio of branded pharmaceuticals such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, BELBUCA, Fortesta Gel, Testim, Aveed, Supprelin LA, and XIAFLEX; U.S. Generic Pharmaceuticals portfolio consists of tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches, and International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American, South African and world markets. It sells generic products primarily in the United States across multiple therapeutic categories.

Another recent and important Endo International plc – Ordinary Shares (NASDAQ:ENDP) news was published by Valuewalk.com which published an article titled: “Endo International plc – Ordinary Shares (ENDP) Collapses Taking Hedge Fund …” on May 06, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: ,

Related posts

Leave a Comment